Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is attractive fundamentally because its Phase 2 CALMA trial for IGC-AD1 has already shown clinically and statistically significant agitation reduction versus placebo in March 2024, de-risking the lead program with human proof-of-concept. The company also reported in August that it reached its original 146-patient enrollment target and is now within 6 additional randomizations of closure, while earlier April progress showed over 80% enrollment, indicating strong operational execution and near-term milestone visibility. With a billion-dollar market potential, and multiple catalysts such as completion of CALMA and the AI beta program in mid-2026, the stock offers a compelling risk-reward profile despite the long development path.

Bears say

IGC Pharma is an early-stage, clinical company with minimal revenue generation, and its Q2 2026 results showed just $0.3 million in revenue against a $2.9 million net loss, highlighting a business model that remains heavily dependent on future scientific and regulatory success. Its Alzheimer’s-focused pipeline may address a large unmet need, but the company still faces significant execution risk because its candidates must prove safety and efficacy in clinical trials, gain regulatory approval, and ultimately achieve commercialization and reimbursement. Given the balance sheet and liquidity risks, ongoing losses, and broad biotech sensitivity to investor sentiment and macroeconomic conditions, the fundamentals support a negative outlook.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Oct 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.